Literature DB >> 17991256

EEG changes and serum anticholinergic activity measured in patients with delirium in the intensive care unit.

K Plaschke1, H Hill, R Engelhardt, C Thomas, R von Haken, M Scholz, J Kopitz, H J Bardenheuer, M Weisbrod, M A Weigand.   

Abstract

The aim of this study was to examine whether serum anticholinergic activity (SAA) is a reliable indicator of delirium in the ICU, and whether there is a significant correlation between SAA and quantitative electroencephalographic (EEG) data in delirious patients. In a prospective cohort study, we assessed ICU patients diagnosed with delirium (n = 37). EEG measurements and blood analysis including SAA were performed 48 h following ICU admission. The presence of delirium was evaluated using the Confusion Assessment Method for critically ill patients in ICU (CAM-ICU). The SAA level was measured using a competitive radioreceptor binding assay for muscarinergic receptors and quantitative EEG was measured using the CATEEM system. We found that, under comparable conditions, patients in the delirium group showed a higher relative EEG theta power and a reduced alpha power (n = 17) than did the non-delirious patients (n = 20). No difference in measured SAA levels were seen; therefore, there was no correlation between SAA and EEG measurements in delirious patients. We conclude that, in contrast to the EEG, the SAA level cannot be proposed as a tool for diagnosing delirium in ICU patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991256     DOI: 10.1111/j.1365-2044.2007.05255.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  20 in total

1.  Early postoperative delirium after open-heart cardiac surgery is associated with decreased bispectral EEG and increased cortisol and interleukin-6.

Authors:  Konstanze Plaschke; Philipp Fichtenkamm; Christoph Schramm; Steffen Hauth; Eike Martin; Markus Verch; Matthias Karck; Jürgen Kopitz
Journal:  Intensive Care Med       Date:  2010-08-06       Impact factor: 17.440

2.  Central Anticholinergic Adverse Effects and Their Measurement.

Authors:  Pasi Lampela; Teemu Paajanen; Sirpa Hartikainen; Risto Huupponen
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 3.  Postoperative delirium.

Authors:  E L Whitlock; A Vannucci; M S Avidan
Journal:  Minerva Anestesiol       Date:  2011-04       Impact factor: 3.051

Review 4.  Biomarkers for delirium--a review.

Authors:  Babar A Khan; Mohammed Zawahiri; Noll L Campbell; Malaz A Boustani
Journal:  J Am Geriatr Soc       Date:  2011-11       Impact factor: 5.562

Review 5.  [Delirium in the intensive care unit].

Authors:  R von Haken; M Gruss; K Plaschke; M Scholz; R Engelhardt; A Brobeil; E Martin; M A Weigand
Journal:  Anaesthesist       Date:  2010-03       Impact factor: 1.041

6.  Electroencephalography and delirium in the postoperative period.

Authors:  B J A Palanca; T S Wildes; Y S Ju; S Ching; M S Avidan
Journal:  Br J Anaesth       Date:  2017-08-01       Impact factor: 9.166

Review 7.  The neuroinflammatory response of postoperative cognitive decline.

Authors:  Susana Vacas; Vincent Degos; Xiaomei Feng; Mervyn Maze
Journal:  Br Med Bull       Date:  2013-04-04       Impact factor: 4.291

Review 8.  Biomarkers of postoperative delirium and cognitive dysfunction.

Authors:  Ganna Androsova; Roland Krause; Georg Winterer; Reinhard Schneider
Journal:  Front Aging Neurosci       Date:  2015-06-09       Impact factor: 5.750

Review 9.  The cognitive impact of anticholinergics: a clinical review.

Authors:  Noll Campbell; Malaz Boustani; Tony Limbil; Carol Ott; Chris Fox; Ian Maidment; Cathy C Schubert; Stephanie Munger; Donna Fick; David Miller; Rajesh Gulati
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

10.  Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium.

Authors:  Christine Thomas; Ute Hestermann; Juergen Kopitz; Konstanze Plaschke; Peter Oster; Martin Driessen; Christoph Mundt; Matthias Weisbrod
Journal:  BMC Neurosci       Date:  2008-09-15       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.